BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CNTO 1959: Phase II started

MorphoSys said Johnson & Johnson's Janssen Biotech Inc. unit began the double-blind, U.S. Phase II X-PLORE trial to compare 5, 15, 50, 100 and 200 mg subcutaneous CNTO 1959 vs. placebo or adalimumab in about 280 patients with moderate to severe plaque-type...

Read the full 188 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >